Danish speciality pharmaceutical company Veloxis Pharmaceuticals A/S (CPH: VELO) has appointed Ulf Meier-Kriesche, MD, as chief scientific officer of Veloxis Pharmaceuticals Inc, the company announced on Thursday.

Veloxis said that his responsibilities will involve overseeing the company's regulatory and medical affairs departments.

Dr Meier-Kriesche is an established board certified nephrologist with over 20 years of practical clinical experience in transplantation. Additionally, he is the author of over 170 scientific publications.

Before joining Veloxis, Dr Meier-Kriesche worked as Bristol-Myers Squibb's (NYSE: BMS) clinical trials lead immunologist. He has also worked for Astellas Pharma (TYO: 4503).

Craig Collard, CEO of Veloxis Pharmaceuticals A/S, said in a statement: "Veloxis is committed to serving the needs of the transplant community and the appointment of Ulf Meier-Kriesche further solidifies that commitment.

"Ulf's background and experience as a transplant nephrologist will help Veloxis be more responsive to the concerns of clinicians and ultimately better support the transplant community."